Clinical Trials Sponsored by AMO Development, LLC

Total 1407 results

AMO Development, LLC

Recruiting

Wavefront-guided LASIK for Monovision Treatment of Myopic Subjects With Presbyopia

Refractive Error

United States
Beat AML, LLC

Recruiting

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Previously Untreated Acute Myeloid Leukemia

United States
Yamo Pharmaceuticals LLC

Completed

Safety of L1-79 in Autism

Autism

United States
Yamo Pharmaceuticals LLC

Active, not recruiting

A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

Autism Spectrum Disorder | Autism

United States
SCRI Development Innovations, LLC
Janssen Research & Development, LLC

Recruiting

Outpatient Administration of Teclistamab for Multiple Myeloma

Multiple Myeloma

United States
CMP Development, LLC

Not yet recruiting

A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients

Edema Due to Heart Failure or Cirrhosis

India
CMP Development, LLC

Completed

Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)

Drug Drug Interaction

India
LipimetiX Development, LLC

Completed

Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia

Hypercholesterolemia | Hyperlipoproteinemia Type II

Australia
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (SELENE)

Lymphoma

United States, France, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Belgium, Israel, Russian Federation, Turkey, Japan, Australia, Sweden, Korea, Republic of, Brazil, Puerto Rico, Poland
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE)

Chronic Graft Versus Host Disease

United States, Australia, Austria, Canada, China, Croatia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Singapore, Spain, Taiwan
Janssen Research & Development, LLC
Pharmacyclics LLC.

Terminated

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

United States, France, Poland, United Kingdom, Germany, Taiwan, Spain, Bulgaria, Romania, Turkey, Ukraine, Canada, Korea, Republic of, Netherlands, Russian Federation, Belgium, Brazil, Hungary, Czechia, Sweden
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Follicular Lymphoma | B Cell Lymphoma | Non-Hodgkin's Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Diffuse Well-differentiated Lymphocytic Lymphoma | B-Cell Diffuse Lymphoma

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

CD20-positive B-cell Non-Hodgkin Lymphoma

United States, France
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Chronic Lymphocytic Leukemia With 17p Deletion | Small Lymphocytic Lymphoma With 17p Deletion

United States, United Kingdom, Belgium, Germany, Turkey, Australia, Canada, New Zealand, Sweden
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants

Healthy Volunteer

Belgium
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

Healthy Volunteer

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Recruiting

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

Leukemia, Lymphocytic, Chronic, B-Cell | Small Lymphocytic Lymphoma

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Enrolling by invitation

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Follicular Lymphoma | Chronic Graft Versus Host Disease | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma

United States, Spain, United Kingdom, Israel, Canada, Belgium, Poland, China, Japan, France, Korea, Republic of, Australia, Russian Federation, Turkey, Sweden, Italy, Mexico, Brazil, Czechia, Ukraine, Hungary, Portugal, Argentina, Col... and more
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (VEGA)

Lymphoma, Mantle-Cell

Taiwan, Thailand, Malaysia, India, Puerto Rico, Spain, Turkey, Czechia, Brazil, Greece, Poland, Sweden, Romania
Pharmacyclics LLC.
Janssen Research & Development, LLC

Active, not recruiting

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

Mantle-Cell Lymphoma

France, Canada, Spain, United States, Hungary, Korea, Republic of, Greece, Australia, Netherlands, Belgium, United Kingdom, Czechia, Germany, Poland, Italy, Turkey, Ukraine
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma

United States, Belgium, France, Germany, United Kingdom
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (Captivate)

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Italy, New Zealand, Poland, Spain
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)

Leukemia, Lymphocytic, Chronic, B-Cell

Canada, Belgium, Netherlands, Spain, Israel, United States, Czechia, Denmark, United Kingdom, France, Russian Federation, Turkey, Poland, Sweden
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States, France, Poland, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Israel, Turkey, Ukraine, Japan, Canada, Greece, Korea, Republic of, Netherlands, Brazil, Russian Federation, Puerto Rico, Australia, I... and more
Pharmacyclics LLC.
Janssen Research & Development, LLC

Active, not recruiting

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease

United States, Spain, Korea, Republic of, Australia, Austria, Canada, France, Germany, Israel, Italy, Netherlands, Russian Federation, United Kingdom
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia

United States, Spain, France, Canada, Germany, Italy, Australia, United Kingdom, Greece
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, China, Belgium, Germany, Spain, Israel, Turkey, Ukraine, Japan, Taiwan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, Brazil, Russian Federation, Argentina, Norway, Swed... and more
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, France, Poland, Belgium, Germany, Spain, Argentina, Colombia, Israel, Portugal, Russian Federation, Turkey, Ukraine, Canada, Greece, Sweden, Korea, Republic of, United Kingdom, Brazil, Mexico, Czechia
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™)

Relapsed or Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Austria, Belgium, France, Ireland, Italy, Poland, Spain, United Kingdom
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, Taiwan, Malaysia, Australia
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Mantle Cell Lymphoma

France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Colombia, Portugal, Ukraine, Canada, Netherlands, Sweden, Korea, Republic of, Chile, Brazil, Russian Federation, Hungary, Ireland, Mexico, Czechia
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, Spain, Belgium, Germany, Russian Federation
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Mantle Cell Lymphoma

United States, France, United Kingdom, Belgium, Spain, Israel, Puerto Rico, Poland, Russian Federation
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765

Healthy Volunteers

United States
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR Jr)

Colitis, Ulcerative

United States, China, Japan
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Plaque Psoriasis

Australia, Spain, Korea, Republic of, Taiwan, Germany
Janssen Research & Development, LLC

Not yet recruiting

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)

Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Korea, Republic of, United Kingdom, United States, Poland, Germany, Brazil, Spain, Taiwan, Hungary, Japan, Canada, Argentina, Australia
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer

Advanced Prostate Cancer

United States, France
Janssen Research & Development, LLC

Recruiting

Global Patient Registry of Inherited Retinal Diseases (EYERD Registry)

Inherited Retinal Diseases

United States, Korea, Republic of, Canada, Denmark, Germany, Spain, France, Italy, Israel, Austria, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (AZALEA)

Hemolytic Disease of the Fetus and Newborn

Israel, Australia, United States, Brazil, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS)

Metastatic Castrate-sensitive Prostate Cancer

United States, France, Germany, Australia, Brazil, Canada, China, Poland, Mexico
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic Atrophy

Netherlands, United States, Belgium, Germany, United Kingdom, Italy, Denmark, Spain, Czechia, Switzerland, Turkey, Canada, Hungary, Portugal, Poland, Australia, Sweden
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2)

Carcinoma, Non-small-Cell Lung

United States, Korea, Republic of, Italy, Israel, Malaysia, United Kingdom, China, Brazil, Spain, Germany, Japan, France
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (METalmark)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, United States, China, Germany, Brazil, Italy, Spain, Turkey, United Kingdom, Poland, Japan, France, Canada
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab

Multiple Myeloma

Korea, Republic of, Russian Federation, Spain, United States, Germany, Greece, Belgium, Denmark, France, Ukraine, China
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA)

Myositis

United States, Korea, Republic of, Italy, United Kingdom, Hungary, Spain, Japan, Czechia, France, Germany, Canada, Mexico, Poland
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

Relapsed/ Refractory Multiple Myeloma

United States, Germany, Spain, France

Clinical Trials Sponsored by AMO Development, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations